Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 2/3 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 2Gastrointestinal 2Head & Neck 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 35Glioblastoma 24Carcinoma, Non-Small-Cell Lung 21Ovarian Neoplasms 14Carcinoma, Hepatocellular 14Brain Neoplasms 14Carcinoma, Renal Cell 13Pancreatic Neoplasms 12Neoplasms 10Neoplasm Metastasis 10Glioma 10Breast Neoplasms 10Colonic Neoplasms 8Astrocytoma 8Melanoma 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Liver Neoplasms 6Gliosarcoma 6Endometrial Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Cancer Metastatic 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Oligodendroglioma 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

Etoposide 18Carboplatin 18pembrolizumab 15Nivolumab 11Cisplatin 11atezolizumab 8Topotecan 8Irinotecan 7Temozolomide 6Paclitaxel 5PM 01183 5Ipilimumab 5Gemcitabine 5olaparib 4Radiotherapy 4Docetaxel 4surufatinib 3durvalumab 3carfilzomib 3Bevacizumab 3veliparib 2trilaciclib 2sacituzumab govitecan 2rovalpituzumab tesirine 2obatoclax 2niraparib 2navitoclax 2lorvotuzumab mertansine 2lenvatinib 2fluzoparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Carcinoma × Bevacizumab × Clear all
NCT02734004 2026-04-20

MEDIOLA

AstraZeneca

Phase 1/2 Active not recruiting
264 enrolled 32 charts
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

Shanghai JMT-Bio Inc.

Phase 1/2 Not yet recruiting
596 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡